23andMe to acquire telemedicine platform company Lemonaid Health for $400M in cash, stock

Under the terms of the deal, 23andMe will acquire Lemonaid for $100 million in cash and $300 million in common stock. The transaction is expected to close by the end of the year.


You may also like

Brent crude oil

Brent crude oil

HRC Steel

HRC Steel